{"nctId":"NCT01453946","briefTitle":"Safety and Maintenance Study of Entocort for Children With Crohn's Disease","startDateStruct":{"date":"2011-12"},"conditions":["Crohn's Disease"],"count":55,"armGroups":[{"label":"Entocort","type":"OTHER","interventionNames":["Drug: Entocort"]}],"interventions":[{"name":"Entocort","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* All male and female subjects must be aged 5 to 17, inclusive, and must not have reached their 18th birthday by the estimated final office visit.\n* All subjects must weight \\>= 15 kg at the time of enrollment.\n* Subjects must have been diagnosed and treated for active Crohn's disease of the ileum and/or ascending colon confirmed by endoscopic and/or radiographic evidence, and/or evidence of mucosal erosions and/or histology and have a PCDAI \\<= 10\n\nExclusion Criteria:\n\n* Subjects who have had any previous intestinal resection proximal to and including the ascending colon.\n* Subjects with evidence of active Crohn's disease (PCDAI \\> 10) and/or stricturing, prestenotic dilatation, clinical evidence of obstruction, perirectal abscess, perirectal disease with active draining fistulas, perforation, or any septic complications.\n* Subjects with morning cortisol level \\<150 nmol/l (5.4 ug/dl) or DHEA-S below normal range for age and gender (NOTE: Subjects from the induction protocol with abnormal morning cortisol/DHEA-S levels at Visit 4, who otherwise meet the eligibility criteria, may be enrolled if the investigator decides that Entocort 6 mg is an appropriate therapy option.","healthyVolunteers":false,"sex":"ALL","minimumAge":"5 Years","maximumAge":"17 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"SECONDARY","title":"PCDAI","description":"Pediatric Crohn's Disease Activity Index. The scale ranges from 0 (no activity) to 100 (high activity)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.9","spread":"3.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":"7.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.9","spread":"8.1"}]}]}]},{"type":"SECONDARY","title":"IMPACT 3","description":"IMPACT-III - A QUALITY OF LIFE QUESTIONNAIRE FOR CHILDREN WITH INFLAMMATORY BOWEL DISEASE","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"146.6","spread":"12.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","spread":"8.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"147.0","spread":"15.5"}]}]}]},{"type":"PRIMARY","title":"Adverse Event","description":"Any kind of adverse event","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":50},"commonTop":["Abdominal pain","Acne","Crohn's disease","Increased appetite","Irritability"]}}}